What the business is, and whether it's a good one at a fair price.
Sells branded pharmaceutical formulations in India and abroad, and through mid-2026 also manufactured active pharmaceutical ingredients (APIs). Domestic Formulations is the largest segment — it markets chronic-therapy drugs under brands such as Naprosyn, launched a new Naprosyn ES (Naproxen + Esomeprazole) combination in July 2026 through a partnership with Archerchem, and is scaling an immunosuppressant portfolio. International Formulations exports formulations to overseas markets. The API business, which contributed Rs 95.06 crore (13.54% of FY26 consolidated revenue), is being transferred on a slump sale basis to a newly formed wholly owned subsidiary, RPG Active Pharma, in which PE investors are committing up to Rs 700 crore; the same subsidiary is separately acquiring 100% of Actis Generics for Rs 80 crore in cash. Raw materials (19.2% of revenue) and employees (20.0% of revenue) are the largest operating costs, with capex at 9.2% and depreciation at 3.0% of revenue. FY26 consolidated revenue totalled Rs 707.52 crore, with Domestic Formulations at Rs 483.5 crore growing 13.8% year-on-year while International Formulations declined 6.7%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from RPG LIFE SCIENCES LTD's filed financials and exchange disclosures
RPG LIFE SCIENCES LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol RPGLIFE.
Yes. The dividend yield is 0.89% at the current price. It paid out 35% of its profit as dividend in FY26.
Effectively yes. It holds ₹130 Cr more cash than debt. Debt stands at 0.03× equity.
On trailing P/E, RPG LIFE SCIENCES LTD ranks 131 of 169 in Pharmaceuticals — cheaper than 23% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session RPG LIFE SCIENCES LTD moves 1.00% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by RPG LIFE SCIENCES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
